Reviva Pharmaceuticals HOLDINGS, Inc. (RVPH) intrinsic value & 10-year financials
Reviva Pharmaceuticals HOLDINGS, Inc. (RVPH) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.47
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 289.8%
- Free cash flow (FY2025)
- —
RVPH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$19.9M | — | — | — | 229.7% |
| FY2024 | — | -$29.9M | — | — | — | 206.3% |
| FY2023 | — | -$39.3M | — | — | — | 331.2% |
| FY2022 | — | -$24.3M | — | — | — | 391.8% |
| FY2021 | — | -$8.5M | — | — | — | — |
| FY2020 | — | -$3.8M | — | — | — | — |
| FY2019 | — | -$846.8K | — | — | — | — |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
REVIVA PHARMACEUTICALS HOLDINGS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
REVIVA PHARMACEUTICALS HOLDINGS, INC. has historically struggled to out-earn its cost of capital, averaging just 2.9% ROIC.
REVIVA PHARMACEUTICALS HOLDINGS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
REVIVA PHARMACEUTICALS HOLDINGS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.